Cytori to Webcast Fourth Quarter and Year End Financial Results on March 7
Cytori to Webcast Fourth Quarter and Year End Financial Results on March 7
SAN DIEGO--(BUSINESS WIRE)-- Cytori Therapeutics (NAS: CYTX) will provide a live webcast of its fourth quarter and year end financial results and business update on Thursday, March 7, 2013 at 5:00 PM Eastern Time.
The dial-in information is as follows:
Dial-In Number: +1.877.402.3914 | |||||
Conference ID: 11509895 |
Prior to the webcast at approximately 4:05 PM Eastern Time on March 7, Cytori will issue its year end earnings release which will review Cytori's fourth quarter and full year performance. CEO Chris Calhoun will give detailed remarks at the start of the call. Please note, Cytori will not be providing a shareholder letter as in past quarters.
The webcast will be available both live and by replay two hours after the call under "Webcasts" on the Company's Investor Relations website (http://ir.cytori.com).
About Cytori
Cytori Therapeutics is developing cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and repair soft tissue defects. Our scientific data suggest ADRCs improve blood flow. As a result, we believe these cells can be applied across multiple "ischemic" conditions. These therapies are made available to the physician and patient at the point-of-care by Cytori's proprietary technologies and products, including the Celution® System product family. www.cytori.com
Cytori Therapeutics
Megan McCormick, +1.858.875.5279
mmccormick@cytori.com
KEYWORDS: United States North America California
INDUSTRY KEYWORDS:
The article Cytori to Webcast Fourth Quarter and Year End Financial Results on March 7 originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
